May I inquire as to the time remaining. The SPEAKER pro tempore. The gentleman from Texas has 13\3/4\ minutes remaining. The gentleman from New Jersey has 11\1/4\ minutes remaining.
Michael Burgess
The Public Record
Michael Clifton Burgess is an American politician and physician who has served as the U.S. Representative for Texas's 26th congressional district since 2003. A member of the Republican Party, Burgess has focused on healthcare policy, leveraging his medical background to inform his legislative work. He has been involved in various committees and has advocated for issues such as medical research and veterans' healthcare. Burgess has also been a vocal supporter of conservative fiscal policies and has participated in discussions surrounding healthcare reform.
Today, we have over 30 million Americans who may be suffering from hearing loss, but only around 20 percent actually go and get hearing aids.
And yet when we do hearings and we talk about problems in the Medicaid system and the Medicare system, the GAO will report back to us that these are high-risk entities that are at high risk for inappropriate payments.
By direction of the Committee on Rules, I call up House Resolution 230 and ask for its immediate consideration. The Clerk read the resolution, as follows: H. Res. 230 Resolved, That upon adoption of this resolution it shall be in order to…
I want to read from a couple of the lines from this op- ed. The Senator states here: ``Privacy is also a cornerstone of consumer protection, with Federal enforcement agencies striking an appropriate balance between innovation and security…
House Resolution 230 provides for a rule to consider a Congressional Review Act resolution which will undo a duplicative regulation put into place by the previous administration in the final hours of that Presidency. The rule brings before…
I thank the men and women of the Federal Trade Commission for all the work they have done over the years in protecting our privacy. Mr. Speaker, I reserve the balance of my time.
Let's continue to build upon these remarkable and bipartisan advancements that put patients first.
Reauthorizing the Medical Device User Fee Agreements and the user fee programs we have previously discussed would increase efficiency at FDA.





